Here’s what you should know:
1. Janssen is conducting the phase 3 trial to create comparative data between the two CD treatment options.
2. Researchers plan to enroll approximately 350 patients into the study, which will take place at up to 100 worldwide sites.
3. The study will conclude in 2020.
4. The treatment phase of the study will take 52 weeks, with a follow-up phase of 76 weeks.
More articles on gastroenterology:
Joint replacement, spine ASC opens in Southern California
Dr. Paul Chin becomes 1st surgeon in Texas to use Catalyst Orthoscience device: 5 takeaways
5 organizations teaming up to tackle antibiotic resistance in outpatient space— 5 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.